PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VKTX vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


VKTXLLY
YTD Return225.63%41.16%
1Y Return510.27%34.54%
3Y Return (Ann)115.04%48.26%
5Y Return (Ann)50.16%51.11%
Sharpe Ratio3.441.29
Sortino Ratio4.871.90
Omega Ratio1.621.26
Calmar Ratio8.671.98
Martin Ratio18.446.53
Ulcer Index28.18%5.80%
Daily Std Dev150.87%29.34%
Max Drawdown-90.41%-68.27%
Current Drawdown-35.87%-14.70%

Fundamentals


VKTXLLY
Market Cap$7.02B$790.25B
EPS-$0.94$9.31
PEG Ratio-0.030.78
Total Revenue (TTM)$436.00K$40.86B
Gross Profit (TTM)$126.00K$33.33B
EBITDA (TTM)-$133.66M$13.78B

Correlation

-0.50.00.51.00.2

The correlation between VKTX and LLY is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

VKTX vs. LLY - Performance Comparison

In the year-to-date period, VKTX achieves a 225.63% return, which is significantly higher than LLY's 41.16% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%JuneJulyAugustSeptemberOctoberNovember
-16.41%
7.52%
VKTX
LLY

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VKTX vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


VKTX
Sharpe ratio
The chart of Sharpe ratio for VKTX, currently valued at 3.44, compared to the broader market-4.00-2.000.002.004.003.44
Sortino ratio
The chart of Sortino ratio for VKTX, currently valued at 4.87, compared to the broader market-4.00-2.000.002.004.006.004.87
Omega ratio
The chart of Omega ratio for VKTX, currently valued at 1.62, compared to the broader market0.501.001.502.001.62
Calmar ratio
The chart of Calmar ratio for VKTX, currently valued at 8.67, compared to the broader market0.002.004.006.008.67
Martin ratio
The chart of Martin ratio for VKTX, currently valued at 18.44, compared to the broader market0.0010.0020.0030.0018.44
LLY
Sharpe ratio
The chart of Sharpe ratio for LLY, currently valued at 1.29, compared to the broader market-4.00-2.000.002.004.001.29
Sortino ratio
The chart of Sortino ratio for LLY, currently valued at 1.90, compared to the broader market-4.00-2.000.002.004.006.001.90
Omega ratio
The chart of Omega ratio for LLY, currently valued at 1.26, compared to the broader market0.501.001.502.001.26
Calmar ratio
The chart of Calmar ratio for LLY, currently valued at 1.98, compared to the broader market0.002.004.006.001.98
Martin ratio
The chart of Martin ratio for LLY, currently valued at 6.53, compared to the broader market0.0010.0020.0030.006.53

VKTX vs. LLY - Sharpe Ratio Comparison

The current VKTX Sharpe Ratio is 3.44, which is higher than the LLY Sharpe Ratio of 1.29. The chart below compares the historical Sharpe Ratios of VKTX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio1.002.003.004.005.00JuneJulyAugustSeptemberOctoberNovember
3.44
1.29
VKTX
LLY

Dividends

VKTX vs. LLY - Dividend Comparison

VKTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.61%.


TTM20232022202120202019201820172016201520142013
VKTX
Viking Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.61%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%3.84%

Drawdowns

VKTX vs. LLY - Drawdown Comparison

The maximum VKTX drawdown since its inception was -90.41%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for VKTX and LLY. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-35.87%
-14.70%
VKTX
LLY

Volatility

VKTX vs. LLY - Volatility Comparison

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 28.83% compared to Eli Lilly and Company (LLY) at 9.85%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
28.83%
9.85%
VKTX
LLY

Financials

VKTX vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items